Showing results (401-410 of 411) with videos related to
Sort By:
Pageof 42
Cancer Research|January 26, 2024
Cotargeting CDK4/6 and BRD4 Promotes Senescence and Ferroptosis Sensitivity in CancerXianbing Zhu, Zheng Fu, Kendall Dutchak, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 20, 2024
Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung CancerJonathan D Spicer, Tina Cascone, Murry W Wynes, et al.Nature Communications|September 21, 2019
Harnessing calcineurin-FK506-FKBP12 crystal structures from invasive fungal pathogens to develop antifungal agentsPraveen R Juvvadi, David Fox, Benjamin G Bobay, et al.Nature|February 1, 2023
Single-cell spatial landscapes of the lung tumour immune microenvironmentMark Sorin, Morteza Rezanejad, Elham Karimi, et al.The New England Journal of Medicine|June 2, 2025
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung CancerPatrick M Forde, Jonathan D Spicer, Mariano Provencio, et al.Nature Communications|February 6, 2019
SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancerYibo Xue, Brian Meehan, Zheng Fu, et al.Nature Cancer|February 5, 2022
Neutrophil oxidative stress mediates obesity-associated vascular dysfunction and metastatic transmigrationSheri A C McDowell, Robin B E Luo, Azadeh Arabzadeh, et al.Cancer Discovery|September 14, 2023
Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform TrialTina Cascone, Gozde Kar, Jonathan D Spicer, et al.The New England Journal of Medicine|May 15, 2024
Perioperative Nivolumab in Resectable Lung CancerTina Cascone, Mark M Awad, Jonathan D Spicer, et al.The Journal of Experimental Medicine|May 11, 2023
Obesity alters monocyte developmental trajectories to enhance metastasisSheri A C McDowell, Simon Milette, Samuel Doré, et al.Pageof 42